Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma
Metrics: PDF 1650 views | HTML 1879 views | ?
Qi Bai1,*, Li Liu1,*, Wei Xi1,*, Jiajun Wang1, Yu Xia1, Yang Qu1, Ying Xiong1, Qilai Long1, Jiejie Xu2, Jianming Guo1
1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
*These authors have contributed equally to this work
Jiejie Xu, email: [email protected]
Jianming Guo, email: [email protected]
Keywords: clear cell renal cell carcinoma, α-GalNAc α-2, 6-sialyltransferase 1, nomogram, overall survival
Received: March 07, 2016 Accepted: July 18, 2016 Published: August 12, 2016
Background: Sialyltransferase ST6GalNAc-1 is highly expressed in tumor cells and associated with tumor aggressiveness and poor prognosis. In the present study, we aimed to investigate the clinical and prognostic significance of sialyltransferase ST6GalNAc-1 in patients with non-metastatic ccRCC.
Results: High expression of ST6GalNAc-1 in tumor tissue was an independent prognostic factor for overall survival (p<0.001) and recurrence free survival (p<0.001) in multivariate analysis. The nomograms could give better prediction for overall survival and recurrence free survival in ccRCC patients.
Methods: 264 patients diagnosed with non-metastatic clear cell renal cell carcinoma were enrolled in the present study. Immunohistochemical staining was performed on tissue microarrays to evaluate the intratumoral ST6GalNAc-1 expression. Kaplan-Meier method and Cox proportional hazard model were applied to assess the prognostic value of ST6GalNAc-1. Nomograms were generated to refine individual risk stratification in ccRCC patients.
Conclusion: ST6GalNAc-1 was an independent adverse prognostic factor for both overall survival and recurrence free survival in patients with non-metastatic ccRCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.